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to the accumulation of IDL particle and may prevent small,Role of hepatic lipase in intermediate-density lipoprotein and
dense LDL formation in HD patients.small, dense low-density lipoprotein formation in hemodialysis
patients.
Background. It has been reported that remnant lipoproteins
and small, dense low-density lipoproteins (LDLs) are risk fac- It has been well known that atherosclerotic vasculartors for cardiovascular disease. To determine whether these
disease frequently occurs in uremic patients receivingrisk factors are present in hemodialysis (HD) patients who
long-term hemodialysis (HD) and that cardiovascularare suffering from a high incidence of atherosclerotic vascular
disease, we measured concentrations of remnant lipoproteins disease is the leading cause of death in these patients
and LDL particle diameter in HD patients and compared these [1, 2]. The mechanisms for developing atherosclerosis in
with controls. We also measured lipoprotein lipase (LPL) and HD patients are multifactorial. However, plasma lipidhepatic triglyceride lipase (HTGL) that play important roles
abnormalities have been identified as significant risk fac-in the generation of remnant lipoproteins and small, dense
tors for cardiovascular disease in such patients. PreviousLDL, and we correlated these changes with plasma lipoprotein
abnormalities in HD patients. studies have revealed that an increase in plasma triglyc-
Methods. Lipoproteins were separated by ultracentrifuga- eride and a decrease in high-density lipoprotein (HDL)
tion. Apoprotein B in very low-density lipoprotein (VLDL), cholesterol concentrations were prominent characteris-and intermediate-density lipoprotein (IDL) fractions were
tics of lipid abnormalities associated with uremic patientsmeasured by a sensitive enzyme-linked immunosorbent assay
[3]. However, recent studies reported that very low-den-method. The average LDL particle diameter was measured by
gradient gel electrophoresis. sity lipoprotein (VLDL) and intermediate-density lipo-
Results. Plasma triglyceride, total cholesterol, and high-den- protein (IDL) were increased in uremic patients without
sity lipoprotein (HDL) cholesterol concentrations were compa- apparent hyperlipidemia [4, 5].rable between HD patients and controls, whereas LDL choles-
Recent epidemiological studies suggest, however, thatterol was significantly lower in HD patients. The average LDL
a predominance of smaller and less dense LDL (small,particle diameter was not significantly different between HD
patients and controls. LDL particle diameter was inversely dense LDL) is highly atherogenic, and it may be a new
related to plasma triglyceride concentrations in all of the sub- risk factor of coronary heart disease [6]. Do these nontra-
jects. VLDL triglyceride, VLDL cholesterol, and VLDL apo- ditional risk factors, for example, small, dense LDL andprotein B were comparable between HD patients and controls.
IDL, increase in HD patients? In this study, we measuredIDL triglyceride, IDL cholesterol, and IDL apoprotein B con-
centrations were all significantly increased in HD patients com- remnant lipoproteins and small, dense LDL in HD pa-
pared with those in controls. LPL mass was not altered, but tients and compared those with controls. Because lipo-
HTGL activity was significantly decreased in HD patients. The protein lipase (LPL) and hepatic triglyceride lipase
HTGL activity was inversely related to IDL concentrations.
(HTGL) play important roles in regulating triglycer-Conclusions. These results suggest that a prominent charac-
ide-rich lipoprotein metabolism and in generating rem-teristic of lipoprotein abnormalities in HD patients is a marked
increase in IDL particle number. In addition, small, dense LDL nant lipoproteins and small, dense LDL, we measured
is not associated with uremic dyslipidemia. Because HTGLs these lipases and investigated their relationships with
promote the conversion from IDL to LDL and the generation plasma lipoprotein abnormalities in HD patients.
of lipid-poor LDL, a decrease in HTGL activity may contribute
METHODSKey words: cardiovascular disease; hepatic triglyceride lipase; interme-
diate-density lipoprotein; small, dense low-density lipoprotein. The subjects in this study were 19 nondiabetic HD
patients and 17 age- and gender-matched controls with 1999 by the International Society of Nephrology
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normal renal function. The HD patients were composed reported [4, 5]. However, we did not find an increased
incidence of small, dense LDL in HD patients. In con-of 17 chronic glomerulonephritis patients and 2 polycys-
tic kidney disease patients. Blood samples were drawn trast, Bofinger et al demonstrated that HD and perito-
from all patients after they fasted over night. VLDL neal dialysis patients had atherogenic lipid profiles that
(density , 1.006), IDL (d 5 1.006 to 1.019), and LDL were associated with a predominance of small, dense
(d 5 1.019 to 1.063) were separated by ultracentrifuga- LDL [10]. Their study also indicated that triglyceride
tion. Apoprotein B concentrations in VLDL and IDL and VLDL cholesterol concentrations were elevated in
were measured by a sensitive enzyme-linked immuno- dialysis patients. In their study, mean plasma triglyceride
sorbent assay (ELISA) method [7]. LDL particle diame- concentrations were significantly high compared with the
ter was measured by 2 to 16% gradient polyacrylamide subjects of our study. This might be a reason that their
gel electrophoresis [8]. HTGL activity in postheparin results were different from ours, as LDL particle diame-
plasma collected 10 minutes after intravenous injection ter was strongly associated with plasma triglyceride con-
of heparin (30 unit/kg body wt) was measured as the rate centrations. In addition, we found that HTGL activity
of radiolabeled fatty acids liberated from a [14C] trioleine was decreased in HD patients and that there were sig-
emulsion in gum arabic. Immunoreactive LPL mass in nificant inverse correlations between HTGL activity and
postheparin plasma was measured by sandwich-enzyme IDL levels. These findings, together with the fact that
immunoassay [9]. Data were expressed as mean 6 sd. HTGL plays critical roles in the conversion of IDL and
Student’s unpaired t-test and Pearson’s simple regression in the generation of lipid-poor LDL, indicate that a re-
analysis were employed for the statistical analysis. P duction in HTGL activity may contribute to the accumu-
values of less than 0.05 were considered significant. lation of IDL particle number and may prevent the gen-
eration of small, dense LDL in HD patients.
In conclusion, our results indicate that a prominent
RESULTS
characteristic of lipid abnormalities in HD patients is a
Plasma triglyceride, total cholesterol, and HDL cho- marked increase in IDL particle number. In our study,
lesterol concentrations were similar to those of our con- small, dense LDL particles were not increased.
trols, whereas LDL cholesterol concentrations were sig-
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